nach oben

Clinical Pharmacokinetics

Erschienen in:

24.01.2022 | Original Research Article

Prediction of Maternal and Fetal Acyclovir, Emtricitabine, Lamivudine, and Metformin Concentrations during Pregnancy Using a Physiologically Based Pharmacokinetic Modeling Approach

verfasst von: Khaled Abduljalil, Amita Pansari, Jia Ning, Masoud Jamei

Erschienen in: Clinical Pharmacokinetics | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Concerns over maternal and fetal drug exposure during pregnancy highlight the need for improved understanding of drug distribution to the fetus through the placental barrier.

Objective

Our objective was to predict maternal and fetal drug disposition using a physiologically based pharmacokinetic (PBPK) modeling approach.

Methods

We used the detailed maternal–placental–fetal PBPK model within the Simcyp Simulator V20 to predict the maternal and fetal drug exposure of acyclovir, emtricitabine, lamivudine, and metformin during pregnancy and at delivery. The dynamic model includes gestational changes to the maternal, fetal, and placental physiological parameters. Placental kinetics were parameterized using published ex vivo data for these four compounds. Amniotic data were included where available. PBPK predictions were compared with the observed data using twofold criteria.

Results

Maternal–fetal PBPK models were developed completely from the bottom up without any parameter adjustments. The PBPK model-predicted exposures matched the observed maternal and umbilical exposure for acyclovir (six maternal studies, all of which all reported umbilical exposure), emtricitabine (six maternal studies, of which four reported umbilical exposure), lamivudine, (five maternal studies, of which four reported umbilical exposure), and metformin (seven studies, of which six reported umbilical exposure). Predicted pharmacokinetic parameters were within twofold of the observed values.

Conclusion

Integration of fetal and maternal system parameters within PBPK models, together with experimental data from ex vivo placental perfusion studies, facilitated and extended the application of the pregnancy PBPK model. Such models can also be used inform clinical trials and maternal/fetal risk assessment following maternally administered drugs or unintended exposure to environmental toxicants.

Nur mit Berechtigung zugänglich

Herring C, McManus A, Weeks A. Off-label prescribing during pregnancy in the UK: an analysis of 18,000 prescriptions in Liverpool Women’s Hospital. Int J Pharm Pract. 2010;18(4):226–9.PubMed

Laroche ML, Blin A, Coubret A, Grau M, Roux B, Aubard Y. Off-label prescribing during pregnancy in France: the NeHaVi cohort. Int J Clin Pharmacol Ther. 2020;58(4):198–208.PubMedCrossRef

Rayburn WF, Turnbull GL. Off-label drug prescribing on a state university obstetric service. J Reprod Med. 1995;40(3):186–8.PubMed

Bouazza N, Foissac F, Hirt D, Urien S, Benaboud S, Lui G, et al. Methodological approaches to evaluate fetal drug exposure. Curr Pharm Des. 2019;25(5):496–504.PubMedCrossRef

Schmidt A, Morales-Prieto DM, Pastuschek J, Frohlich K, Markert UR. Only humans have human placentas: molecular differences between mice and humans. J Reprod Immunol. 2015;108:65–71.PubMedCrossRef

De Sousa MM, Lui G, Zheng Y, Pressiat C, Hirt D, Valade E, et al. A physiologically-based pharmacokinetic model to predict human fetal exposure for a drug metabolized by several CYP450 pathways. Clin Pharmacokinet. 2017;56(5):537–50.CrossRef

Schalkwijk S, Buaben AO, Freriksen JJM, Colbers AP, Burger DM, Greupink R, et al. Prediction of fetal darunavir exposure by integrating human ex-vivo placental transfer and physiologically based pharmacokinetic modeling. Clin Pharmacokinet. 2018;57(6):705–16.PubMedCrossRef

Abduljalil K, Badhan RKS. Drug dosing during pregnancy-opportunities for physiologically based pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2020;47(4):319–40.PubMedCrossRef

Abduljalil K, Furness P, Johnson TN, Rostami-Hodjegan A, Soltani H. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2012;51(6):365–96.PubMedCrossRef

10.

Abduljalil K, Johnson TN, Rostami-Hodjegan A. Fetal physiologically-based pharmacokinetic models: systems information on fetal biometry and gross composition. Clin Pharmacokinet. 2018;57(9):1149–71.PubMedCrossRef

11.

Abduljalil K, Jamei M, Johnson TN. Fetal physiologically based pharmacokinetic models: systems information on the growth and composition of fetal organs. Clin Pharmacokinet. 2019;58(2):235–62.PubMedCrossRef

12.

Abduljalil K, Pan X, Clayton R, Johnson TN, Jamei M. Fetal physiologically based pharmacokinetic models: systems information on fetal cardiac output and its distribution to different organs during development. Clin Pharmacokinet. 2021;60(6):741–57.PubMedCrossRef

13.

Abduljalil K, Jamei M, Johnson TN. Fetal physiologically based pharmacokinetic models: systems information on fetal blood components and binding proteins. Clin Pharmacokinet. 2020;59(5):629–42.PubMedCrossRef

14.

Zhang Z, Imperial MZ, Patilea-Vrana GI, Wedagedera J, Gaohua L, Unadkat JD. Development of a novel maternal-fetal physiologically based pharmacokinetic model I: insights into factors that determine fetal drug exposure through simulations and sensitivity analyses. Drug Metab Dispos. 2017;45(8):920–38.PubMedPubMedCentralCrossRef

15.

Abduljalil K, Pan X, Pansari A, Jamei M, Johnson TN. A preterm physiologically based pharmacokinetic model part I: physiological parameters and model building. Clin Pharmacokinet. 2020;59(4):485–500.PubMedCrossRef

16.

Barker G, Boyd RD, D’Souza SW, Donnai P, Fox H, Sibley CP. Placental water content and distribution. Placenta. 1994;15(1):47–56.PubMedCrossRef

17.

Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006;95(6):1238–57.PubMedCrossRef

18.

Neuhoff S, Gaohua L, Burt H, Jamei M, Li L, Tucker GT, et al. Accounting for transporters in renal clearance: towards a mechanistic kidney model (Mech KiM). In: Sugiyama Y, Steffansen B, editors. Transporters in drug development AAPS advances in the pharmaceutical sciences series. Springer, New York. 2013.

19.

Rhodin MM, Anderson BJ, Peters AM, Coulthard MG, Wilkins B, Cole M, et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol. 2009;24(1):67–76.PubMedCrossRef

20.

Blackburn S. Maternal, fetal and neonatal physiology: a clinical perspective. 3rd ed. Philadelphia: Saunders Elsevier; 2007.

21.

Underwood MA, Gilbert WM, Sherman MP. Amniotic fluid: not just fetal urine anymore. J Perinatol. 2005;25(5):341–8.PubMedCrossRef

22.

Abduljalil K, Pansari A, Jamei M. Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy. J Pharmacokinet Pharmacodyn. 2020;47(4):361–83.PubMedCrossRef

23.

Haddad J, Langer B, Astruc D, Messer J, Lokiec F. Oral acyclovir and recurrent genital herpes during late pregnancy. Obstet Gynecol. 1993;82(1):102–4.PubMed

24.

Leung DT, Henning PA, Wagner EC, Blasig A, Wald A, Sacks SL, et al. Inadequacy of plasma acyclovir levels at delivery in patients with genital herpes receiving oral acyclovir suppressive therapy in late pregnancy. J Obstet Gynaecol Can. 2009;31(12):1137–43.PubMedPubMedCentralCrossRef

25.

Kimberlin DF, Weller S, Whitley RJ, Andrews WW, Hauth JC, Lakeman F, et al. Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy. Am J Obstet Gynecol. 1998;179(4):846–51.PubMedCrossRef

26.

Frenkel LM, Brown ZA, Bryson YJ, Corey L, Unadkat JD, Hensleigh PA, et al. Pharmacokinetics of acyclovir in the term human pregnancy and neonate. Am J Obstet Gynecol. 1991;164(2):569–76.PubMedCrossRef

27.

Matsuzaki T, Scotcher D, Darwich AS, Galetin A, Rostami-Hodjegan A. Towards further verification of physiologically-based kidney models: predictability of the effects of urine-flow and urine-ph on renal clearance. J Pharmacol Exp Ther. 2019;368(2):157–68.PubMedCrossRef

28.

Laskin OL, Longstreth JA, Saral R, de Miranda P, Keeney R, Lietman PS. Pharmacokinetics and tolerance of acyclovir, a new anti-herpesvirus agent, in humans. Antimicrob Agents Chemother. 1982;21(3):393–8.PubMedPubMedCentralCrossRef

29.

Vergin H, Kikuta C, Mascher H, Metz R. Pharmacokinetics and bioavailability of different formulations of aciclovir. Arzneimittelforschung. 1995;45(4):508–15.PubMed

30.

Liao MZ, Flood Nichols SK, Ahmed M, Clark S, Hankins GD, Caritis S, et al. Effects of Pregnancy on the Pharmacokinetics of Metformin. Drug Metab Dispos. 2020;48(4):264–71.PubMedPubMedCentralCrossRef

31.

Eyal S, Easterling TR, Carr D, Umans JG, Miodovnik M, Hankins GD, et al. Pharmacokinetics of metformin during pregnancy. Drug Metab Dispos. 2010;38(5):833–40.PubMedPubMedCentralCrossRef

32.

Bergagnini-Kolev MC, Hebert MF, Easterling TR, Lin YS. Pregnancy Increases the renal secretion of N(1)-methylnicotinamide, an endogenous probe for renal cation transporters, in patients prescribed metformin. Drug Metab Dispos. 2017;45(3):325–9.PubMedPubMedCentralCrossRef

33.

Henderson GI, Hu ZQ, Johnson RF, Perez AB, Yang Y, Schenker S. Acyclovir transport by the human placenta. J Lab Clin Med. 1992;120(6):885–92.PubMed

34.

Gilstrap LC, Bawdon RE, Roberts SW, Sobhi S. The transfer of the nucleoside analog ganciclovir across the perfused human placenta. Am J Obstet Gynecol. 1994;170(4):967–72.PubMedCrossRef

35.

Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother. 1995;39(12):2759–64.PubMedPubMedCentralCrossRef

36.

Lewis LD, Fowle AS, Bittiner SB, Bye A, Isaacs PE. Human gastrointestinal absorption of acyclovir from tablet duodenal infusion and sipped solution. Br J Clin Pharmacol. 1986;21(4):459–62.PubMedPubMedCentralCrossRef

37.

Amini H, Javan M, Gazerani P, Ghaffari A, Ahmadiani A. Lack of bioequivalence between two aciclovir tablets in healthy subjects. Clin Drug Investig. 2008;28(1):47–53.PubMedCrossRef

38.

Gilead Sciences. Emtriva® prescribing information. 2012. http://www.gilead.com/pdf/emtriva_pi.pdf. Accessed 5 Apr 2021.

39.

Hirt D, Urien S, Rey E, Arrive E, Ekouevi DK, Coffie P, et al. Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Antimicrob Agents Chemother. 2009;53(3):1067–73.PubMedCrossRef

40.

De Sousa MM, Chetty M. Are standard doses of renally-excreted antiretrovirals in older patients appropriate: a PBPK study comparing exposures in the elderly population with those in renal impairment. Drugs R D. 2019;19(4):339–50.CrossRef

41.

De Sousa MM, Hirt D, Vinot C, Valade E, Lui G, Pressiat C, et al. Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models. Br J Clin Pharmacol. 2016;81(4):646–57.CrossRef

42.

Zong J, Chittick GE, Wang LH, Hui J, Begley JA, Blum MR. Pharmacokinetic evaluation of emtricitabine in combination with other nucleoside antivirals in healthy volunteers. J Clin Pharmacol. 2007;47(7):877–89.PubMedCrossRef

43.

Blum MR, Chittick GE, Begley JA, Zong J. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. J Clin Pharmacol. 2007;47(6):751–9.PubMedCrossRef

44.

Wang LH, Begley J, St Claire RL, Harris J, Wakeford C, Rousseau FS. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res Hum Retroviruses. 2004;20(11):1173–82.PubMedCrossRef

45.

Rousseau FS, Kahn JO, Thompson M, Mildvan D, Shepp D, Sommadossi JP, et al. Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil). J Antimicrob Chemother. 2001;48(4):507–13.PubMedCrossRef

46.

Valade E, Treluyer JM, Bouazza N, Ghosn J, Foissac F, Benaboud S, et al. Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients. Antimicrob Agents Chemother. 2014;58(4):2256–61.PubMedPubMedCentralCrossRef

47.

Stek AM, Best BM, Luo W, Capparelli E, Burchett S, Hu C, et al. Effect of pregnancy on emtricitabine pharmacokinetics. HIV Med. 2012;13(4):226–35.PubMed

48.

Colbers AP, Hawkins DA, Gingelmaier A, Kabeya K, Rockstroh JK, Wyen C, et al. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. AIDS. 2013;27(5):739–48.PubMedCrossRef

49.

Liu XI, Momper JD, Rakhmanina N, van den Anker JN, Green DJ, Burckart GJ, et al. Physiologically based pharmacokinetic models to predict maternal pharmacokinetics and fetal exposure to emtricitabine and acyclovir. J Clin Pharmacol. 2020;60(2):240–55.PubMedCrossRef

50.

Valade E, Treluyer JM, Dabis F, Arrive E, Pannier E, Benaboud S, et al. Modified renal function in pregnancy: impact on emtricitabine pharmacokinetics. Br J Clin Pharmacol. 2014;78(6):1378–86.PubMedPubMedCentralCrossRef

51.

Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet. 1999;36(1):41–66.PubMedCrossRef

52.

FDA. Lamuvidine ID: 4157751. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf.

53.

Benaboud S, Treluyer JM, Urien S, Blanche S, Bouazza N, Chappuy H, et al. Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women. Antimicrob Agents Chemother. 2012;56(2):776–82.PubMedPubMedCentralCrossRef

54.

Chappuy H, Treluyer JM, Jullien V, Dimet J, Rey E, Fouche M, et al. Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother. 2004;48(11):4332–6.PubMedPubMedCentralCrossRef

55.

Mandelbrot L, Peytavin G, Firtion G, Farinotti R. Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women. Am J Obstet Gynecol. 2001;184(2):153–8.PubMedCrossRef

56.

Moodley J, Moodley D, Pillay K, Coovadia H, Saba J, van Leeuwen R, et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis. 1998;178(5):1327–33.PubMedCrossRef

57.

Yeh RF, Rezk NL, Kashuba AD, Dumond JB, Tappouni HL, Tien HC, et al. Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. Antimicrob Agents Chemother. 2009;53(6):2367–74.PubMedPubMedCentralCrossRef

58.

Bloom SL, Dias KM, Bawdon RE, Gilstrap LC 3rd. The maternal-fetal transfer of lamivudine in the ex vivo human placenta. Am J Obstet Gynecol. 1997;176(2):291–3.PubMedCrossRef

59.

Challier JC. Criteria for evaluating perfusion experiments and presentation of results. Contrib Gynecol Obstet. 1985;13:32–9.PubMedCrossRef

60.

Yuen GJ, Morris DM, Mydlow PK, Haidar S, Hall ST, Hussey EK. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J Clin Pharmacol. 1995;35(12):1174–80.PubMedCrossRef

61.

van Leeuwen R, Lange JM, Hussey EK, Donn KH, Hall ST, Harker AJ, et al. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS. 1992;6(12):1471–5.PubMedCrossRef

62.

Heald AE, Hsyu PH, Yuen GJ, Robinson P, Mydlow P, Bartlett JA. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother. 1996;40(6):1514–9.PubMedPubMedCentralCrossRef

63.

Yuen GJ, Lou Y, Bumgarner NF, Bishop JP, Smith GA, Otto VR, et al. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother. 2004;48(1):176–82.PubMedPubMedCentralCrossRef

64.

Charles B, Norris R, Xiao X, Hague W. Population pharmacokinetics of metformin in late pregnancy. Ther Drug Monit. 2006;28(1):67–72.PubMedCrossRef

65.

Hughes RC, Gardiner SJ, Begg EJ, Zhang M. Effect of pregnancy on the pharmacokinetics of metformin. Diabet Med. 2006;23(3):323–6.PubMedCrossRef

66.

Tertti K, Laine K, Ekblad U, Rinne V, Ronnemaa T. The degree of fetal metformin exposure does not influence fetal outcome in gestational diabetes mellitus. Acta Diabetol. 2014;51(5):731–8.PubMedCrossRef

67.

Kovo M, Haroutiunian S, Feldman N, Hoffman A, Glezerman M. Determination of metformin transfer across the human placenta using a dually perfused ex vivo placental cotyledon model. Eur J Obstet Gynecol Reprod Biol. 2008;136(1):29–33.PubMedCrossRef

68.

de Oliveira Baraldi C, Lanchote VL, de Jesus Antunes N, de Jesus Ponte Carvalho TM, Dantas Moises EC, Duarte G, et al. Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome. Eur J Clin Pharmacol. 2011;67(10):1027–33.PubMedCrossRef

69.

Christensen T, Klebe JG, Bertelsen V, Hansen HE. Changes in renal volume during normal pregnancy. Acta Obstet Gynecol Scand. 1989;68(6):541–3.PubMedCrossRef

70.

Bailey RR, Rolleston GL. Kidney length and ureteric dilatation in the puerperium. J Obstet Gynaecol Br Commonw. 1971;78(1):55–61.PubMedCrossRef

71.

Reznicek J, Ceckova M, Cerveny L, Müller F, Staud F. Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters. Xenobiotica. 2017;47(1):77–85.PubMedCrossRef

72.

Bousquet L, Pruvost A, Didier N, Farinotti R, Mabondzo A. Emtricitabine: Inhibitor and substrate of multidrug resistance associated protein. Eur J Pharm Sci. 2008;35(4):247–56.PubMedCrossRef

73.

De Sousa MM, Hirt D, Urien S, Valade E, Bouazza N, Foissac F, et al. Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women. Br J Clin Pharmacol. 2015;80(5):1031–41.CrossRef

74.

Ceckova M, Reznicek J, Ptackova Z, Cerveny L, Muller F, Kacerovsky M, et al. Role of ABC and solute carrier transporters in the placental transport of lamivudine. Antimicrob Agents Chemother. 2016;60(9):5563–72.PubMedPubMedCentralCrossRef

75.

Choi MK, Jin QR, Jin HE, Shim CK, Cho DY, Shin JG, et al. Effects of tetraalkylammonium compounds with different affinities for organic cation transporters on the pharmacokinetics of metformin. Biopharm Drug Dispos. 2007;28(9):501–10.PubMedCrossRef

76.

Sata R, Ohtani H, Tsujimoto M, Murakami H, Koyabu N, Nakamura T, et al. Functional analysis of organic cation transporter 3 expressed in human placenta. J Pharmacol Exp Ther. 2005;315(2):888–95.PubMedCrossRef

77.

Anoshchenko O, Prasad B, Neradugomma NK, Wang J, Mao Q, Unadkat JD. Gestational age-dependent abundance of human placental transporters as determined by quantitative targeted proteomics. Drug Metab Dispos. 2020;48(9):735–41.PubMedPubMedCentralCrossRef

78.

Kovo M, Kogman N, Ovadia O, Nakash I, Golan A, Hoffman A. Carrier-mediated transport of metformin across the human placenta determined by using the ex vivo perfusion of the placental cotyledon model. Prenat Diagn. 2008;28(6):544–8.PubMedCrossRef

79.

Tertti K, Ekblad U, Heikkinen T, Rahi M, Ronnemaa T, Laine K. The role of organic cation transporters (OCTs) in the transfer of metformin in the dually perfused human placenta. Eur J Pharm Sci. 2010;39(1–3):76–81.PubMedCrossRef

80.

Muller F, Weitz D, Mertsch K, Konig J, Fromm MF. Importance of OCT2 and MATE1 for the cimetidine-metformin interaction: insights from investigations of polarized transport in single- and double-transfected MDCK cells with a focus on perpetrator disposition. Mol Pharm. 2018;15(8):3425–33.PubMedCrossRef

81.

Dallmann A, Ince I, Solodenko J, Meyer M, Willmann S, Eissing T, et al. Physiologically based pharmacokinetic modeling of renally cleared drugs in pregnant women. Clin Pharmacokinet. 2017;56(12):1525–41.PubMedCrossRef

82.

Jogiraju VK, Avvari S, Gollen R, Taft DR. Application of physiologically based pharmacokinetic modeling to predict drug disposition in pregnant populations. Biopharm Drug Dispos. 2017;38(7):426–38.PubMedCrossRef

83.

Xia B, Heimbach T, Gollen R, Nanavati C, He H. A simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pregnancy. AAPS J. 2013;15(4):1012–24.PubMedPubMedCentralCrossRef

84.

Song L, Yu Z, Xu Y, Li X, Liu X, Liu D, et al. Preliminary physiologically based pharmacokinetic modeling of renally cleared drugs in Chinese pregnant women. Biopharm Drug Dispos. 2020;41(6):248–267. https://doi.org/10.1002/bdd.2243.CrossRefPubMed

85.

Mian P, Allegaert K, Conings S, Annaert P, Tibboel D, Pfister M, et al. Integration of placental transfer in a fetal-maternal physiologically based pharmacokinetic model to characterize acetaminophen exposure and metabolic clearance in the fetus. Clin Pharmacokinet. 2020;59(7):911–25.PubMedPubMedCentralCrossRef

86.

Freriksen JJM, Schalkwijk S, Colbers AP, Abduljalil K, Russel FGM, Burger DM, et al. Assessment of maternal and fetal dolutegravir exposure by integrating ex vivo placental perfusion data and physiologically-based pharmacokinetic modeling. Clin Pharmacol Ther. 2020;107(6):1352–61.PubMedPubMedCentralCrossRef

87.

Modena AB, Fieni S. Amniotic fluid dynamics. Acta Biomed. 2004;75(Suppl 1):11–3.PubMed

88.

Hague WM, Davoren PM, McIntyre D, Norris R, Xiaonian XCB. Metformin crosses the placenta: a modulator for fetal insulin resistance? BMJ. 2003;327:880.CrossRef

Titel: Prediction of Maternal and Fetal Acyclovir, Emtricitabine, Lamivudine, and Metformin Concentrations during Pregnancy Using a Physiologically Based Pharmacokinetic Modeling Approach
verfasst von: Khaled Abduljalil
Amita Pansari
Jia Ning
Masoud Jamei
Publikationsdatum: 24.01.2022
Verlag: Springer International Publishing
Erschienen in: Clinical Pharmacokinetics / Ausgabe 5/2022
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-021-01103-0

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Prediction of Maternal and Fetal Acyclovir, Emtricitabine, Lamivudine, and Metformin Concentrations during Pregnancy Using a Physiologically Based Pharmacokinetic Modeling Approach

Abstract

Background

Objective

Methods

Results

Conclusion

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Background

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2022

Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients

“De-Shrinking” EBEs: The Solution for Bayesian Therapeutic Drug Monitoring

Implications of Bariatric Surgery on the Pharmacokinetics of Antiretrovirals in People Living with HIV

Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis

Caspofungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-Abdominal Infections: A Prospective Cohort Study

Transition from Syringe to Autoinjector Based on Bridging Pharmacokinetics and Pharmacodynamics of the P2Y12 Receptor Antagonist Selatogrel in Healthy Subjects